McFarlane Neil F.'s Form 4 filing
Zevra Therapeutics, Inc. (ZVRA) · filed Feb 2, 2026
- Accession no.
- 0001681098-26-000002
- Filed
- Feb 2, 2026
- Trade date
- Jan 29-Feb 2, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $853.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McFarlane Neil F.CIK 0001681098 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2026 | Common Stock | MOption exerciseAcquired | +233,334 | – | – | 455,350 | Direct | |
| Feb 2, 2026 | Common Stock | SSaleDisposed | −91,000 | $9.38 | −$853,580 | 364,350 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 29, 2026 | Common Stock | AGrant or awardAcquired | +125,000 | $0.00 | $0 | 125,000 | Direct | |
| Jan 29, 2026 | Common Stock | AGrant or awardAcquired | +250,000 | $0.00 | $0 | 250,000 | Direct | |
| Jan 31, 2026 | Common Stock | MOption exerciseDisposed | −233,334 | $0.00 | $0 | 233,333 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.